Multi-Stakeholder Approach Helped Push SPC Waiver Up The EU Agenda, Says Medicines For Europe
This article was originally published in SRA
Executive Summary
Medicines for Europe, the association that represents companies marketing generics, biosimilars and 'value-added' medicines, has called on its members to press the European Commission to introduce a manufacturing waiver for drugs still protected by a supplementary protection certificate (SPC) 'as soon as possible.'